NMDA receptor (glycine site, antagonist)

Class

small molecule; the label states 'the mechanism by which felbamate exerts its anticonvulsant activity is unknown', but names two specific in-vitro binding activities

Pathway

acts as an antagonist at the glycine recognition site of the NMDA receptor-ionophore complex, and shows weak inhibitory effects on GABA-receptor binding; demonstrates activity in maximal electroshock and pentylenetetrazol-induced seizure models.

The N-methyl-D-aspartate (NMDA) receptor is a subtype of glutamate receptor that forms an ion channel permeable to calcium and other ions when activated. Its activation requires both glutamate binding and occupancy of a separate co-agonist site by glycine; without glycine bound, the channel cannot open efficiently even when glutamate is present. Excessive or poorly regulated activity at this receptor contributes to abnormal, synchronized firing of neurons, a hallmark of seizure activity, and also plays a role in neuronal injury after excitotoxic insults. A compound that antagonizes the glycine site reduces the probability that the NMDA channel opens, thereby dampening excitatory neurotransmission without needing to block the glutamate site or the ion channel pore itself. This approach is one of several strategies used to develop anticonvulsant medicines, alongside drugs that enhance inhibitory GABAergic signaling or that block voltage-gated sodium channels. In this particular case, the compound has additionally been shown, in laboratory binding studies, to weakly inhibit binding at GABA receptors, though this is considered a minor, secondary activity rather than the main proposed mechanism. Notably, the precise contribution of glycine-site antagonism to the drug's overall anticonvulsant effect in patients has not been definitively established, illustrating that even well-characterized binding activities do not always fully explain a medicine's clinical action.